查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929572

全球腹主动脉腹部主动脉血管瘤血管支架系统市场（依器械类型、动脉瘤类型、手术类型和最终用户划分）预测，2026-2032年

Endovascular AAA Stent Graft System Market by Device Type, Aneurysm Type, Procedure Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，腹部主动脉血管瘤血管支架物系统市值将达到 11.2 亿美元，到 2026 年将成长至 12.1 亿美元，到 2032 年将达到 18.3 亿美元，复合年增长率为 7.17%。

主要市场统计数据
基准年 2025 11.2亿美元
预计年份：2026年 12.1亿美元
预测年份：2032年 18.3亿美元
复合年增长率 (%) 7.17%

本文概述了推动血管支架应用的技术进步、临床工作流程和相关人员的期望。

腹部主动脉血管瘤的血管内修復术已从一种创新替代方案发展成为血管外科的核心支柱，这得益于器械设计、影像引导和手术全期管理技术的进步。如今，临床医师期望血管支架系统能够在适应不同动脉瘤解剖结构和病患合併症的同时，兼顾贴合度、输送精准度和长期耐久性。因此，器械研发人员和医疗服务提供者正携手合作，致力于开发能够降低手术复杂性、缩短住院时间并改善病患短期和长期预后的解决方案。

器械设计、影像导引规划和传输模式的创新正在从根本上重塑腹部主动脉血管瘤（AAA）血管内治疗的临床管道和应用趋势。

血管内动脉瘤修復领域正经历变革性的转变，涵盖器械创新、手术操作和医疗保健系统政策等各个层面。器械设计的进步如今更加重视模组化和患者个人化，使临床医生能够更精准地处理肾旁动脉瘤和胸腹主动脉瘤等复杂解剖结构。影像和规划软体也在同步发展，实现了三维手术模拟和更精确的着陆区评估，从而减少了术中意外情况，并使器械选择与解剖结构要求更加匹配。

本文全面检验了近期美国贸易行动对供应链韧性、筹资策略以及临床应用血管内主动脉装置的影响。

2025年推出的贸易政策变化给依赖全球供应链获取血管支架组件、无菌包装和专用输送工具的公司和医疗机构带来了新的挑战。关税调整可能会增加进口原材料和成品的到岸成本，改变全球製造地的经济格局，并促使采购团队重新评估与供应商的关係。这些连锁反应将波及诸多领域，包括生产速度、库存管理以及供应商与医院供应链团队之间协商的合约条款。

从详细的分割观点出发，将器械分类、动脉瘤解剖结构、治疗环境和手术紧急程度与临床需求和商业策略联繫起来。

了解细分市场的细微差别对于协调临床能力、产品系列和商业性策略至关重要。在评估诸如穿支血管移植、髂动脉分支血管移植和标准血管移植等器械分类时，可以清楚地看到，每一类都针对不同的解剖和治疗需求。穿支血管移植旨在处理肾动脉附近的血管分支，需要精确的术前规划和客製化尺寸。而髂动脉分支血管移植则专注于维持涉及髂总动脉的动脉瘤中的髂内动脉血流。标准血管移植在简单的肾臟下解剖结构中仍然至关重要，因为现成的解决方案可以简化物流和手术准备。

对医疗基础设施、报销制度和临床能力对重点地区医疗服务采用趋势的影响进行比较评估

地理位置对血管内介入治疗的普及模式、监管管道和临床服务结构有显着影响。美洲地区拥有成熟的血管内介入治疗项目，并致力于扩大社区医院和门诊中心的覆盖范围，其完善的报销体系鼓励了手术的普及。此外，该地区的临床群体累积了大量真实世界数据，製造商和医疗系统可以利用这些数据来不断改进器械，并制定循证的推广通讯协定。

从公司层面来看，实证差异化、策略伙伴关係和服务能力备受重视，这些因素会影响临床医师招募和采购决策。

血管内血管支架领域的企业竞争格局取决于产品差异化、临床证据的累积以及透过培训和服务来支持临床医生的能力。成熟的全球医疗设备製造商拥有足够的生产规模、监管方面的专业知识和广泛的商业性网络，能够支援多中心註册研究和长期疗效研究。而专注于血管医疗设备的製造商则更着重于技术差异化、快速改进输送系统以及与高容量中心密切合作，以提升器械在复杂解剖结构中的应用能力。

整合产品开发、临床培训、供应链韧性和支付方合作的策略和营运建议，以加速永续应用。

行业领导者应采取组合式策略，使产品开发、临床证据和商业性执行与医疗服务提供者和患者不断变化的需求保持一致。投资于能够适应不同解剖结构的模组化设备平台，既能扩大临床覆盖范围，又能降低库存管理的复杂性。同时，他们应优先考虑完善的上市后证据项目和註册登记，以检验长期疗效，并为与支付方就价值导向方案的讨论提供支持。

本报告清楚描述了用于得出研究结果的证据来源和分析方法，包括临床医生访谈、监管资讯综合和检验通讯协定。

本执行摘要的研究以对血管外科医生、介入放射科医生、采购人员和供应链主管的定性调查为基础，并结合对监管申报文件、临床实验室数据和同行评审文献的系统分析。主要研究结果透过结构化访谈和专家小组讨论收集，确保高容量中心、门诊手术机构和血管专科计画的代表均有参与，从而涵盖营运多样性和临床观点。

最终综合分析将技术进步、临床实务变革和商业性需求整合起来，为相关人员得出策略性结论。

技术创新、不断演进的医疗服务模式以及监管要求的交汇融合，正在重塑腹部主动脉血管瘤内治疗的格局。器械朝向模组化和解剖结构特异性解决方案的演进，使临床医生能够更精准地治疗更复杂的解剖结构，而影像规划工具则降低了术中不确定性。这些临床进展，加上营运模式的转变（将合适的病例转移到门诊和专科中心），对器械组合和临床医生培训提出了新的要求。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 依器械类型分類的腹部主动脉血管瘤血管支架系统市场

  • 窗户类型
  • 髂动脉分支类型
  • 标准型

9. 依动脉瘤类型分類的腹部主动脉血管瘤血管支架系统市场

  • 肾下动脉类型
  • 肾臟旁型
  • 在肾动脉上
  • 胸腹部

10. 依手术类型分類的腹部主动脉血管瘤血管支架系统市场

  • 择期手术
  • 紧急状况

第十一章 依最终用户分類的腹部主动脉血管瘤血管支架系统市场

  • 门诊手术中心
  • 医院
  • 血管专科中心

12.腹部主动脉血管瘤血管支架系统市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 依组别分類的腹部主动脉血管瘤血管支架系统市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国腹部主动脉血管瘤血管支架系统市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国腹主动脉腹部主动脉血管瘤血管支架系统市场

17. 中国腹部主动脉血管瘤血管支架系统市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bentley InnoMed GmbH
  • Bolton Medical, Inc.
  • Boston Scientific Corporation
  • Braile Biomedica Industria e Comercio SA
  • CR Bard, Inc.
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Cordis Corporation
  • CryoLife, Inc.
  • Endologix, Inc.
  • Getinge AB
  • Jotec GmbH
  • LeMaitre Vascular, Inc.
  • Lombard Medical, Inc.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • Shanghai MicroPort Endovascular MedTech Group Co., Ltd.
  • Terumo Corporation
  • TriVascular Technologies, Inc.
  • Vascutek Ltd.
  • WL Gore & Associates, Inc.
Product Code: MRR-0A3806951827

The Endovascular AAA Stent Graft System Market was valued at USD 1.12 billion in 2025 and is projected to grow to USD 1.21 billion in 2026, with a CAGR of 7.17%, reaching USD 1.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.12 billion
Estimated Year [2026] USD 1.21 billion
Forecast Year [2032] USD 1.83 billion
CAGR (%) 7.17%

Contextual overview that situates technological advances clinical workflows and stakeholder expectations driving modern endovascular AAA stent graft implementation

Endovascular repair of abdominal aortic aneurysms has moved from an innovative alternative to a core pillar of vascular surgery practice, driven by advances in device design, imaging guidance, and perioperative management. Clinicians now expect stent graft systems to balance conformability, delivery precision, and long-term durability while accommodating diverse aneurysm anatomies and patient comorbidities. As a result, device developers and healthcare providers are aligning around solutions that reduce procedural complexity, shorten hospital stays, and improve short- and long-term patient outcomes.

At the same time, hospitals and specialty centers are recalibrating operational pathways to integrate hybrid operating environments, advanced preoperative planning tools, and multidisciplinary teams. These shifts create both opportunities and responsibilities for stakeholders across the value chain. Manufacturers must invest in clinical evidence and training, while providers must adapt procurement strategies and clinical workflows. In parallel, payers and health systems increasingly emphasize value-based metrics and post-market surveillance, prompting greater collaboration between clinical leaders and industry to demonstrate real-world effectiveness and safety.

This introduction frames the subsequent sections by outlining the technical, clinical, and organizational factors that determine adoption and sustained use of endovascular stent graft systems. By foregrounding patient-centered outcomes and operational feasibility, stakeholders can better prioritize investments and partnerships that drive reliable, reproducible care for aneurysm patients.

How innovation in device design imaging guided planning and care delivery models is fundamentally reshaping clinical pathways and adoption dynamics in endovascular AAA care

The landscape of endovascular aneurysm repair is undergoing transformative shifts that span device innovation, procedural practice, and health system policy. Advances in device design now prioritize modularity and patient-specific customization, allowing clinicians to address complex anatomies such as juxtarenal and thoracoabdominal aneurysms with greater precision. Imaging and planning software have evolved in parallel, enabling three-dimensional procedural simulations and more accurate landing-zone assessments, thereby reducing intraoperative surprises and improving alignment between device selection and anatomical demands.

Concurrently, care delivery models are shifting toward less invasive pathways with an emphasis on same-day or short-stay procedures where clinically appropriate. Ambulatory surgery centers and specialty vascular centers are increasingly equipped to perform elective endovascular repairs, which changes demand patterns for inventory, training, and device configurations. Moreover, the growth of endovascular expertise among vascular surgeons and interventional radiologists has broadened procedural indications and refined patient selection criteria, improving outcomes for appropriately selected patients.

Financial and regulatory pressures are also reshaping innovation incentives. Payers are demanding robust real-world evidence and long-term outcome data, which in turn drives manufacturers to invest in registries, post-market studies, and health economic analyses. Together, these technological, clinical, and policy-driven forces are redefining competitive differentiation in the field and setting a higher bar for safety, effectiveness, and cost-efficiency.

Comprehensive examination of how recent United States trade measures influence supply chain resilience procurement strategy and clinical access to endovascular aortic devices

Trade policy shifts introduced in 2025 have introduced a new layer of complexity for companies and healthcare providers that rely on global supply chains for stent graft components, sterile packaging, and specialized delivery tools. Tariff changes can increase landed costs for imported raw materials and finished devices, alter the economics of global manufacturing footprints, and prompt procurement teams to reassess supplier relationships. These ripple effects are felt across manufacturing cadence, inventory management, and contracting terms negotiated between suppliers and hospital supply chain teams.

As tariffs create pressure on unit costs, manufacturers may pursue a range of strategic responses including partial vertical integration of critical component production, selective regional manufacturing, and nearshoring to mitigate exposure to cross-border duties. From the provider perspective, purchasing groups and health systems will intensify price benchmarking and may shift toward longer-term agreements that stabilize unit pricing and guarantee supply continuity. At the same time, clinical teams must anticipate potential changes to device availability and plan accordingly to avoid procedural delays, especially for urgent and emergency cases.

Regulatory oversight and reimbursement dynamics will further mediate these impacts. Payers examining overall treatment costs may apply greater scrutiny to device selection and perioperative pathways, accelerating adoption of cost-effective clinical protocols. In short, tariffs alter commercial calculus and operational planning across the value chain, necessitating proactive supply chain resilience and price management strategies to preserve access and maintain care quality.

Detailed segmentation perspective linking device classes aneurysm anatomies care settings and procedural urgency to clinical requirements and commercial strategies

A nuanced view of segmentation is essential for aligning clinical capabilities with product portfolios and commercial approaches. When assessing device type categories such as fenestrated, iliac branch, and standard grafts, it becomes clear that each class addresses distinct anatomic and therapeutic needs. Fenestrated devices are engineered to accommodate branch vessels near the renal arteries, demanding precise preoperative planning and customized sizing, while iliac branch solutions focus on preserving hypogastric flow in aneurysms involving the common iliac artery. Standard grafts remain indispensable for straightforward infrarenal anatomies where off-the-shelf solutions can simplify logistics and procedural setup.

Anatomy-driven segmentation across infrarenal, juxtarenal, suprarenal, and thoracoabdominal aneurysm types carries critical implications for device selection, procedural risk profiles, and perioperative resource allocation. Juxtarenal and suprarenal anatomies frequently require adjunctive maneuvers or advanced device features to secure adequate proximal fixation, while thoracoabdominal cases often necessitate hybrid approaches and multidisciplinary planning. These complexity gradients influence inventory strategies and clinician training priorities.

End-user segmentation among ambulatory surgery centers, hospitals, and specialty vascular centers highlights divergent operational models. Ambulatory settings emphasize throughput and simplified device configurations that support rapid turnover, whereas hospitals and specialty centers must maintain the capability to manage high-complexity cases and emergencies. Procedure-type segmentation between elective and emergency interventions further dictates device availability, with emergency workflows requiring immediate access to versatile, reliable graft options and protocols to support rapid decision-making. Collectively, these segmentation lenses inform product design imperatives, clinical training investments, and commercial engagement models.

Regional comparative assessment describing how healthcare infrastructure reimbursement and clinical capacity drive varied adoption trajectories across major global regions

Geographic dynamics materially affect adoption patterns, regulatory pathways, and the structure of clinical services. In the Americas, established endovascular programs coexist with initiatives that expand access into community hospitals and ambulatory centers, and the region benefits from well-developed reimbursement frameworks that facilitate procedural uptake. Clinical communities in this region also generate large volumes of real-world data, which manufacturers and health systems use to inform iterative device improvements and evidence-based adoption protocols.

Across Europe Middle East & Africa, regulatory diversity and heterogeneous reimbursement policies shape a mosaic of adoption speeds and clinical practices. Certain European markets emphasize rigorous health technology assessment and comparative effectiveness data, while other countries prioritize rapid access to innovation through conditional pathways. In many parts of the Middle East and Africa, investment in vascular infrastructure is rising, creating opportunities for targeted product deployment and training partnerships that build local procedural capacity.

Asia-Pacific exhibits a broad spectrum of capabilities, from highly advanced tertiary centers in urban hubs to regions where infrastructure investment is accelerating. Countries in this region are notable for rapid adoption of minimally invasive techniques and for fostering local manufacturing ecosystems. Regional differences in population demographics, prevalence of comorbid disease, and hospital infrastructure lead to distinct product requirements and service models, creating both challenges and opportunities for companies seeking sustainable regional strategies.

Company-level perspective emphasizing evidence-driven differentiation strategic partnerships and service capabilities that influence clinician adoption and procurement decisions

Competitive dynamics among companies in the endovascular stent graft space are shaped by product differentiation, clinical evidence generation, and the ability to support clinicians through training and service. Established global medical device manufacturers bring scale in manufacturing, regulatory expertise, and broad commercial reach, enabling them to support multicenter registries and longitudinal outcome studies. At the same time, specialized vascular device companies focus on technical differentiation, rapid iteration of delivery systems, and close collaboration with high-volume centers to refine device features for complex anatomies.

Strategic alliances and targeted acquisitions are common mechanisms to expand device portfolios, access complementary technologies, or accelerate geographic reach. Companies that prioritize real-world evidence, structured training programs for implanters, and comprehensive clinical support are better positioned to demonstrate value to payers and institutions. Additionally, service-oriented offerings such as digital planning platforms, proctorship networks, and integrated sterilization and logistics solutions enhance competitive positioning by reducing barriers to adoption for hospitals and specialty centers.

From a commercial standpoint, successful players balance investment in innovation with pragmatic attention to supply chain reliability and pricing transparency. Those that can translate clinical benefits into demonstrable improvements in perioperative efficiency, patient outcomes, and total episode costs will maintain durable relationships with healthcare systems and proceduralists.

Strategic and operational recommendations that align product development clinical training supply chain resilience and payer engagement to accelerate sustainable adoption

Industry leaders should take a portfolio approach that aligns product development, clinical evidence, and commercial execution with the evolving needs of providers and patients. Invest in modular device platforms that can be configured for a range of anatomies, thereby reducing inventory complexity while expanding clinical applicability. Parallel efforts should prioritize robust post-market evidence programs and registries to validate long-term outcomes and support payer discussions focused on value.

Strengthen supply chain resilience through diversification of component sources and selective regionalization of manufacturing to mitigate tariff exposure and shorten lead times. Engage early and collaboratively with high-volume clinical centers to co-design training curricula and simulation-based proctoring that accelerate safe clinician proficiency. In addition, develop clear pathways for ambulatory adoption by packaging device offerings with streamlined procedural checklists and logistics solutions that support fast turnover without compromising safety.

Finally, cultivate payer partnerships by aligning clinical evidence with health economic analyses that demonstrate impact on length of stay, complication reduction, and downstream resource utilization. By synchronizing product innovation, clinician enablement, and reimbursement strategy, manufacturers and providers can jointly expand appropriate access to endovascular solutions while maintaining fiscal sustainability.

Clear explanation of the evidence sources and analytic approach including clinician interviews regulatory synthesis and triangulation protocols used to develop the report insights

The research underpinning this executive summary combined primary qualitative engagement with vascular surgeons, interventional radiologists, procurement leaders, and supply chain executives alongside systematic synthesis of regulatory filings, clinical trial data, and peer-reviewed literature. Primary insights were gathered through structured interviews and expert panels, ensuring representation from high-volume centers, ambulatory surgery environments, and specialty vascular programs to capture operational diversity and clinical perspectives.

Secondary research involved targeted review of regulatory approvals, device labeling, and published outcomes studies to triangulate evidence on device performance, procedural workflows, and post-market surveillance findings. Data synthesis emphasized cross-validation between clinician experience and documented clinical outcomes to reduce bias. The methodology also incorporated scenario analysis to assess the operational implications of supply chain disruptions and policy changes on device availability and procurement strategies.

Throughout the research process, findings were iteratively reviewed with clinical advisors and industry stakeholders to refine conclusions and ensure practical applicability. The resulting insights reflect a blend of qualitative clinician judgment and documented clinical data, providing a balanced foundation for strategic decision-making.

Closing synthesis that aligns technological progress clinical practice transformation and commercial imperatives into a cohesive set of strategic conclusions for stakeholders

The confluence of technological innovation, evolving care delivery models, and regulatory expectations is reshaping the landscape for endovascular abdominal aortic aneurysm interventions. Device evolution toward modularity and anatomically tailored solutions is enabling clinicians to treat increasingly complex anatomies with greater precision, while imaging and planning tools reduce intraoperative uncertainty. These clinical advances are complemented by operational shifts that move appropriate cases into ambulatory and specialty settings, creating new demands for device portfolios and clinician training.

At the same time, external pressures such as tariff changes and payer emphasis on value compel manufacturers and providers to invest in supply chain resilience, rigorous post-market evidence, and demonstrable cost-effectiveness. Regional heterogeneity requires nuanced strategies that reflect local regulatory frameworks, infrastructure maturity, and provider capabilities. For industry leaders, success will depend on integrating product innovation with practical service offerings, targeted clinical support, and clear health economic narratives.

In summary, stakeholders who prioritize adaptable device platforms, clinician enablement, and robust evidence-generation will be best positioned to enhance patient outcomes while navigating commercial and operational headwinds in the evolving endovascular AAA environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endovascular AAA Stent Graft System Market, by Device Type

  • 8.1. Fenestrated
  • 8.2. Iliac Branch
  • 8.3. Standard

9. Endovascular AAA Stent Graft System Market, by Aneurysm Type

  • 9.1. Infrarenal
  • 9.2. Juxtarenal
  • 9.3. Suprarenal
  • 9.4. Thoracoabdominal

10. Endovascular AAA Stent Graft System Market, by Procedure Type

  • 10.1. Elective
  • 10.2. Emergency

11. Endovascular AAA Stent Graft System Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Vascular Centers

12. Endovascular AAA Stent Graft System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endovascular AAA Stent Graft System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endovascular AAA Stent Graft System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Endovascular AAA Stent Graft System Market

16. China Endovascular AAA Stent Graft System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. B. Braun Melsungen AG
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bentley InnoMed GmbH
  • 17.9. Bolton Medical, Inc.
  • 17.10. Boston Scientific Corporation
  • 17.11. Braile Biomedica Industria e Comercio S.A.
  • 17.12. C.R. Bard, Inc.
  • 17.13. Cardinal Health, Inc.
  • 17.14. Cook Medical LLC
  • 17.15. Cordis Corporation
  • 17.16. CryoLife, Inc.
  • 17.17. Endologix, Inc.
  • 17.18. Getinge AB
  • 17.19. Jotec GmbH
  • 17.20. LeMaitre Vascular, Inc.
  • 17.21. Lombard Medical, Inc.
  • 17.22. Medtronic plc
  • 17.23. Meril Life Sciences Pvt. Ltd.
  • 17.24. Merit Medical Systems, Inc.
  • 17.25. MicroPort Scientific Corporation
  • 17.26. Shanghai MicroPort Endovascular MedTech Group Co., Ltd.
  • 17.27. Terumo Corporation
  • 17.28. TriVascular Technologies, Inc.
  • 17.29. Vascutek Ltd.
  • 17.30. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY FENESTRATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY FENESTRATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY FENESTRATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ILIAC BRANCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ILIAC BRANCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ILIAC BRANCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY INFRARENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY INFRARENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY INFRARENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY JUXTARENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY JUXTARENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY JUXTARENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUPRARENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUPRARENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUPRARENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY THORACOABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY THORACOABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY THORACOABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ELECTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ELECTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ELECTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY EMERGENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY EMERGENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY EMERGENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. GCC ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. G7 ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NATO ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY ANEURYSM TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA ENDOVASCULAR AAA STENT GRAFT SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)